47 TWENTYFOURSEVENBIOPHARMA Issue 2 / June 2025 ALFASIGMA This vision places the customer-centric approach at the heart of Morpho’s growth strategy. It ensures that third-party manufacturing is executed with the same rigour, quality and care as Alfasigma’s own products, fostering trust-based, long-term relationships. In an increasingly complex and collaborative pharmaceutical landscape, Morpho aims to be a reliable strategic partner, helping clients navigate challenges, accelerate product development and deliver high-value solutions to patients, while safeguarding intellectual property. Morpho’s growth path is clear: to become a leading tech-driven specialty CDMO within a pharmaceutical group. By integrating a customerfocused mindset, technological innovation, customised high-quality services and strong IP protection, Morpho considers itself to be uniquely positioned to shape the future of pharmaceutical and nutraceutical development and manufacturing. Comprehensive global network Morpho operates through several manufacturing facilities in Italy – Alanno, Pomezia, Trezzano Rosa and Sermoneta, as well as in the United States at Shreveport, Louisiana. These sites support a wide array of pharmaceutical forms, including sterile injectables (vials, ampoules, pre-filled syringes and cartridges), lyophilised products, sterile powders (including vaccines and hormone-based products), oral solids and semi-solids. In addition to its manufacturing capabilities, Morpho also includes the LABIO 4.0 Research and Development Centre in Pomezia (Rome) as an integral part of its network. The centre houses state-of-the-art laboratories specialising in pharmaceutical technology and analytical chemistry. WILL CHU Editor 24/7 BIOPHARMA
RkJQdWJsaXNoZXIy MjY2OTA4MA==